Caspase-3 Protein is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target. [1]
Caspase-3 (Cysteine-ASPartic protease-3), also known as CPP32, apopain, or SCA-1, is a member of the cysteine-aspartic protease (caspase) family that plays a central and critical role in programmed cell death (apoptosis). In the context of neurodegenerative diseases, caspase-3 activation represents a crucial executer of neuronal death pathways in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and related disorders 1. [2]
Caspase-3 belongs to the family of aspartate-specific cysteine proteases, classified as an effector caspase (along with caspase-6 and caspase-7), functioning downstream of initiator caspases (caspase-8, -9, -10) in the apoptosis cascade. The systematic name is EC 3.4.22.56, and the gene is located on chromosome 4q33 1. [3]
The enzyme exists as an inactive zymogen (procaspase-3, 32 kDa) that requires proteolytic activation to generate the active heterotetramer. This activation involves cleavage at specific aspartic acid residues and subsequent dimerization of the p17/p12 subunits. [4]
Caspase-3 contains distinct structural domains: [5]
N-terminal prodomain (~30 amino acids): Contains the caspase recruitment domain (CARD) that mediates interactions with upstream adaptor proteins like Apaf-1 and allows for activation by initiator caspases
Large subunit (p17, ~150 amino acids, 17 kDa): Contains the catalytic cysteine residue (Cys163) in the active site motif QACXG (where X is typically R or G), which is essential for proteolytic activity
Small subunit (p12, ~80 amino acids, 12 kDa): Forms the dimerization interface and contributes to substrate binding
The three-dimensional structure reveals a classic caspase fold with a central six-stranded β-sheet flanked by α-helices, with the active site formed at the interface between the two subunits. [6]
Caspase-3 demonstrates high specificity for the tetrapeptide sequence DEXD (Asp-Glu-X-Asp), with optimal cleavage occurring after DXXD motifs. The S1 pocket shows absolute specificity for aspartate, while the S2-S4 pockets accommodate various amino acids, with preference for glutamic acid at S2 1. [7]
Over 200 cellular substrates have been identified, classified into several functional groups: [8]
Structural and Cytoskeletal Proteins [9]
DNA Repair and Maintenance Enzymes [10]
Signal Transduction Proteins
Anti-apoptotic Proteins
Cell Cycle Regulators
The cleavage of these substrates leads to the characteristic morphological and biochemical features of apoptosis, including chromatin condensation, DNA fragmentation, membrane blebbing, and formation of apoptotic bodies 2.
Caspase-3 activation occurs through a tightly regulated proteolytic cascade:
Initiator caspase activation: Caspase-8 (extrinsic pathway) or caspase-9 (intrinsic/mitochondrial pathway) become activated first through autoproteolysis or induced proximity
Procaspase-3 cleavage: Initiator caspases cleave procaspase-3 at specific aspartic acid residues (Asp175 in the interdomain linker and Asp9 at the N-terminus)
Autocatalytic processing: The cleaved procaspase-3 undergoes autocatalytic processing to generate the mature p17/p12 subunits
Dimerization: Two p17/p12 heterodimers form the active heterotetramer (32 kDa), which can then cleave substrates
Active site formation: The catalytic cysteine in the p17 subunit aligns with the substrate-binding pocket created at the dimer interface
This activation cascade ensures that caspase-3 activation occurs only after upstream death signals have been triggered, providing an important checkpoint in the cell death program.
In Alzheimer's disease, caspase-3 contributes to multiple pathological processes, making it a central player in neuronal death 2:
Amyloid-β-Induced Apoptosis
Amyloid-β42 oligomers trigger caspase-3 activation through multiple interconnected pathways:
Studies demonstrate that caspase-3 activation represents a final common pathway for Aβ42-induced neuronal death, and caspase-3 inhibitors protect against Aβ toxicity in cellular and animal models 2.
Tau Cleavage and Pathology
Caspase-3 cleaves tau protein at Asp421, generating a truncation product with enhanced pathogenic properties 3:
The caspase-cleaved tau fragment (Δtau421) is detected in AD brain tissue and is considered a pathogenic intermediate that drives disease progression 3.
Synaptic Loss and Dysfunction
Caspase-3-mediated cleavage of synaptic proteins contributes to early synaptic dysfunction, a hallmark of AD:
Correlation with Disease Progression
Caspase-3 activation correlates strongly with AD pathology:
In Parkinson's disease, caspase-3 plays multiple interconnected roles in dopaminergic neuron death 4:
α-Synuclein Cleavage
Caspase-3 cleaves α-synuclein at multiple sites, generating pathogenic fragments:
These cleaved fragments:
Studies show that caspase-3 cleavage of α-synuclein is increased in PD brain tissue, and inhibition of cleavage reduces α-synuclein toxicity 4.
Mitochondrial Dysfunction and Dopaminergic Neuron Vulnerability
Dopaminergic neurons are particularly vulnerable to caspase-3-mediated apoptosis due to their unique characteristics:
LRRK2 Interactions
Mutations in LRRK2 (the most common genetic cause of familial PD) significantly affect caspase-3 signaling:
PINK1/Parkin Pathway Interactions
The PINK1/parkin mitophagy pathway intersects with caspase-3 in complex ways:
In ALS, caspase-3 activation contributes to progressive motor neuron death 5:
SOD1 Mutations
Mutant Cu/Zn superoxide dismutase (SOD1) proteins trigger caspase-3 activation through:
TDP-43 Pathology
TAR DNA-binding protein 43 (TDP-43) aggregation, a hallmark of ALS:
Mechanisms of Activation in ALS
Multiple interconnected mechanisms drive caspase-3 activation:
Caspase-3 plays complex and sometimes paradoxical roles in Huntington's disease:
Mutant Huntingtin Cleavage
Mutant huntingtin (mHTT) protein is cleaved by caspase-3 at multiple sites:
These fragments:
Caspase-3 is a major mediator of neuronal death after stroke and cerebral ischemia:
Reperfusion Injury
Blood flow restoration paradoxically increases damage:
Excitotoxicity
Glutamate-induced excitotoxicity activates caspase-3:
Neuroprotective Strategies
Caspase-3 inhibition is neuroprotective in animal models:
Several classes of caspase-3 inhibitors have been developed for neuroprotection 6:
Peptide Inhibitors
Non-Peptide Inhibitors
Natural Products with Caspase-3 Inhibitory Activity
Despite promising preclinical data, significant challenges remain:
Gene Therapy Approaches
Modulation of Upstream Pathways
Cell-Type Specific Targeting
Caspase-3 activity serves as a potential biomarker for neurodegeneration 6:
Caspase-3 in ferroptosis: Non-apoptotic role in iron-dependent cell death, distinct from classical apoptosis
Tau propagation: Caspase-cleaved tau fragments spread between neurons through synaptic connections
Microglial functions: Caspase-3 in neuroinflammation and microglial survival
Necroptosis crosstalk: Caspase-3 can cleave key necroptosis proteins (RIPK1, RIPK3)
Pyroptosis connections: Links between apoptosis and pyroptosis pathways
Epigenetic regulation: Non-coding RNAs (miRNAs, lncRNAs) regulating caspase-3
Single-cell analysis: Cell-type specific caspase-3 activation patterns
Caspase-3 interacts with numerous proteins in the apoptosis network:
Inhibitors
Activators
Scaffolds and Adaptors
Caspase-3 serves as a central hub integrating multiple cell death pathways:
Caspase-3 represents a central executor of neuronal death in neurodegenerative diseases. Its roles in AD, PD, ALS, HD, and stroke are multifaceted, involving substrate cleavage, protein aggregation, synaptic dysfunction, and neuroinflammation. While significant progress has been made in understanding its functions, significant challenges remain in translating this knowledge into effective therapies. The development of brain-penetrant, selective caspase-3 inhibitors and the identification of reliable biomarkers remain key research priorities for the neurodegenerative disease field.
Caspase-3 employs a classic cysteine protease catalytic mechanism:
[
The active site contains:- Oxyanion hole: Stabilize- S1 pocket: Absolute specificity for aspartate
Caspase-3 expression is regulated at multiple levels:
Phosphorylation
Nitrosylation
Glycosylation
Caspase-3 distribution in neurons:
**Cas- Embryonic- Neural tube closure defects
Conditional Knockout Models
Transgenic Overexpression
| Disease | Primary Trigger | Caspase-3 Role | Therapeutic Targ|---------|-----------------|---| AD | Amyloid-β, tau | Executor, tau cleavage | High potentia| PD | α-Synuclein, mitochondria | Executor, α-synuclein cleavage | High potential |
| ALS | SOD1, TDP-43 | Executor | Moderate potential |
| HD | Mutant huntingtin | Fragment generation | Dual role |
| Stroke | Ischemia | Executor | Proven in models |
Caspase- Neuroinflammation modulation
Yuan et al. Caspase-3 activation in Parkinson's disease models (2010). 2010. ↩︎
Das et al. Caspase-3 and cognitive decline (2015). 2015. ↩︎
Hyman et al. Caspase activation in AD (2014). 2014. ↩︎
D'Amelio et al. Caspase-3 in synaptic plasticity (2012). 2012. ↩︎
Friedlander et al. Caspase inhibition in neurodegeneration (2003). 2003. ↩︎
Onyango et al. Mitochondrial apoptosis in PD (2005). 2005. ↩︎
Mattson, Apoptosis in neurodegenerative disorders (2000). 2000. ↩︎
Wolfe et al. Caspase-3 substrates in neurodegeneration (2013). 2013. ↩︎
Henderson et al. Caspase activation and tau pathology (2016). 2016. ↩︎
Matsushita et al. Alpha-synuclein cleavage by caspase-3 (2005). 2005. ↩︎